| 1 |
南月敏．肝硬化并发症诊治现状及展望[J]．中华肝脏病杂志，2017，25(4): 241-245.
|
| 2 |
Pantham G, Mullen KD.Practical Issues in the Management of Overt Hepatic Encephalopathy[J]. Gastroenterol Hepatol, 2017, 13(11): 659-665.
|
| 3 |
Bannas P, Roldán-Alzate A, Johnson KM, et al.Longitudinal Monitoring of Hepatic Blood Flow before and after TIPS by Using 4D-Flow MR Imaging[J]. Radiology, 2016, 281(2): 574-582.
|
| 4 |
Cavai A, Mercea V, Anton O, et al.Therapeutic Challenges for Symptomatic Portal Cavernoma Cholangiopathy[J]. J Gastrointestin Liver Dis, 2016, 25(3): 395-399.
|
| 5 |
Owen JM, Gaba RC.Transjugular Intrahepatic Portosystemic Shunt Dysfunction: Concordance of Clinical Findings, Doppler Ultrasound Examination, and Shunt Venography[J]. J Clin Imaging Sci, 2016, 6: 29.
|
| 6 |
Zhang YB, Lu Y, Wu WD, at al.Indocyanine green retention is a potential prognostic indicator after splenectomy and pericardial devascularization for cirrhotic patients[J]. Hepatobiliary Pancreat Dis Int, 2016, 15(4): 386-390.
|
| 7 |
Pan HC, Chen YJ, Lin JP, at al.Proteinuria can predict prognosis after liver transplantation[J]. BMC Surg, 2016, 16(1): 63.
|
| 8 |
Takami T, Terai S, Sakaida I. Stem cell therapy in chronic liver disease[J]. Curr Opin Gastroenterol, 2012, 28(3): 203-208.
|
| 9 |
Nicolas CT, Hickey RD, Chen HS, et al.Concise Review: Liver Regenerative Medicine: From Hepatocyte Transplantation to Bioartificial Livers and Bioengineered Grafts[J]. Stem Cells, 2017, 35(1): 42-50.
|
| 10 |
Kim JK, Kim SJ, Kim Y, et al.Long-Term Follow-Up of Patients After Autologous Bone Marrow Cell Infusion for Decompensated Liver Cirrhosis[J]. Cell Transplant, 2017, 26(6): 1059-1066.
|
| 11 |
Nicolas CT, Wang Y, Nyberg SL.Cell therapy in chronic liver disease[J]. Curr Opin Gastroenterol, 2016, 32(3): 189-94.
|
| 12 |
Cantz T, Sharma AD, Ott M. Concise review: Cell therapies for hereditary metabolic liver diseases-concepts, clinical results, and future developments[J]. Stem Cells, 2015, 33(4): 1055-1062.
|
| 13 |
Borhofen SM, Gerner C, Lehmann J, et al.The Royal Free Hospital-Nutritional Prioritizing Tool is an independent predictor of deterioration of liver function and survival in cirrhosis[J]Dig Dis Sci, 2016, 61(6): 1735-1743.
|
| 14 |
Mullen KD, Sanyal AJ, Bass NM, et al.Rifaximin is safe and well tolerated for long-term maintenance of remission from overt hepatic encephalopathy[J]Clin Gastroenterol Hepatol, 2014, 12(8): 1390-1397.e2.
|
| 15 |
Pan XN, Zheng LQ, Lai XH.Bone marrow-derived mesenchymal stem cell therapy for decompensated liver cirrhosis: a meta-analysis[J]. World J Gastroenterol, 2014, 20(38): 14051-14057.
|
| 16 |
Levine P, McDaniel K, Francis H, et al.Molecular mechanisms of stem cell therapy in alcoholic liver disease[J]. Dig Liver Dis, 2014, 46(5): 391-397.
|
| 17 |
刘保池．肝炎后失代偿期肝硬化的治疗与手术技巧[J]国际外科学杂志，2017，44(1): 35-37.
|
| 18 |
Liu B, Chen X, Wang Y, et al.Curative effect of hepatic portal venous administration of autologous bone marrow in AIDS patients with decompensated liver cirrhosis[J]. Cell Death Dis, 2013, 4: e739.
|
| 19 |
刘保池，李垒，司炎辉，等．失代偿肝硬化合并胆囊结石的自体骨髓肝内输注治疗[J]．肝胆胰外科杂志，2016，28(1): 10-12.
|
| 20 |
刘保池，冯铁男，李垒．自体骨髓对失代偿期肝硬化合并小肝癌的治疗[J]．肝胆胰外科杂志，2017，29(3): 188-191.
|